Medications

FDA approves Litfulo for teens, adults with alopecia areata

The U.S. Food and Drug Administration has approved Litfulo (ritlecitinib) for adults and adolescents aged 12 years and older with severe alopecia areata at a recommended dose of 50 mg. Approval of Litfulo was granted to Pfizer.

Oncology & Cancer

Researchers uncover up to 100 potential drug targets for cancer

Protein researchers from the Novo Nordisk Foundation Center for Protein Research at the University of Copenhagen have used mass spectrometry-based proteomics to uncover a number of proteins that could play a critical role ...

page 4 from 30